ArticleFrontiers in oncology2025
MR radiomics in assessment of consistency of pituitary macroadenoma: can T1-weighted contrast enhanced image improve diagnostic performance of T2-weighted image?
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To evaluate and compare the efficacy of radiomics models derived from T2-weighted and/or contrast-enhanced T1-weighted (CET1) images in assessing pituitary macroadenoma consistency, and to validate their performance stability under varying MRI field strengths and scanner vendors. Methods: A total of 133 patients with pathologically proven pituitary macroadenomas (35 fibrous, 98 non-fibrous) were retrospectively included. Three logistic regression models were constructed: a Results: In the test dataset, the T2-CET1 combined model outperformed both the independent CET1 and T2 models, achieving an AUC of 0.86, accuracy of 83.3%, sensitivity of 83.3%, and specificity of 83.8%. This compares favorably with the Conclusions: Combining CET1 with T2 improves prediction performance for pituitary macroadenoma consistency. However, the T2 model demonstrates greater stability across different equipment than either the CET1 or combined models.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.